TheraVida, a new biotech based in San Mateo, Calif., has raised seed funding from Sanderling Ventures, VentureWire reports (subscription required). The company, which doesn’t seem to have a Web site (a possible stub site is here), is researching possible drugs for urological problems.
According to VentureWire, the seed funding was less than $1 million, although the company may seek a larger first funding round by the end of the year. TheraVida has one employee, a former researcher at TheraVance.
VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.